Arbutus Biopharma Corp (NASDAQ:ABUS)
| 4.04 Delayed Data As of Jan 22 |  +0.08 / +2.02%Today’s Change | 0.88 Today|||52-Week Range 9.02 | +13.80% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $343.9M |
Company Description
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
Contact Information
Arbutus Biopharma Corp. 701 Veterans Circle Warminster Pennsylvania 18974 |
Employees
Shareholders
| Mutual fund holders | 6.18% |
| Individual stakeholders | 23.66% |
| Other institutional | 20.86% |
Top Executives
| William H. Collier | President, Chief Executive Officer & Director |
| David C. Hastings | Chief Financial & Accounting Officer |
| Michael J. Sofia | Chief Scientific Officer |
| Elizabeth Howard | Chief Compliance Officer, EVP & General Counsel |
| Michael J. McElhaugh | Chief Business Officer |
